Autopsy report · NCT04602507

Ivermectin in Adults With Severe COVID-19.

“Lack of severe COVID-19 cases in the place of study”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year before it stopped.
• 75 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

CES University

Sponsor type

University, hospital or other

Conditions

Covid19; Severe Acute Respiratory Syndrome

Interventions

Ivermectin; Placebo

Participants

75

Sites

1

Countries

Colombia

Trials that died the same way

• Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection
  “lack of Covid-19 patients” (84% match in meaning)
• The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury
  “Study ended early due to COVID-19” (80% match in meaning)
• Transgender Therapeutic Support Groups
  “Study unable to be conducted due to COVID.” (78% match in meaning)
• Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19
  “Number of Covid-19 cases who need intensive care have greatly reduced, it is very difficult to find eligible patients for the study” (78% match in meaning)
• Vitamin D Status and Bone Health of Older Adults in Care Facilities
  “COVID-19, study status being reviewed on an ongoing basis.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.